Bolt Biotherapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The company is a clinical-stage cancer immunotherapy developer and reported no product-sales revenue; collaboration revenue is its only revenue source.
Financial results and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $1.4m | $1.4m | $3.3m | $2.2m |
| Research and development expense | $15.6m | $18.9m | $30.3m | $37.3m |
| General and administrative expense | $5.6m | $5.5m | $11.2m | $11.8m |
| Net loss | $18.1m | $22.7m | $35.0m | $46.3m |
| Net loss per share, basic and diluted | $0.48 | $0.61 | $0.93 | $1.25 |
- Operating loss was $19.8m for Q2 and $38.2m for the first half. Interest income was $1.8m and $3.2m, respectively. Gross margin is not separately presented; the filing reports collaboration revenue and operating expenses.
- Six-month operating cash outflow was $38.5m, versus $45.1m in 2022. Investing activities provided $42.6m, primarily from marketable-security maturities exceeding purchases; financing provided $0.1m.
- At June 30, cash and cash equivalents were $13.5m, short-term investments $112.4m, and long-term investments $31.2m—$157.1m combined. Current assets were $130.7m and current liabilities $17.6m. Accumulated deficit was $330.1m.
- The company reported no outstanding debt. Operating lease liabilities totaled $21.5m, including $2.6m current and $18.9m non-current.
Material changes and business developments
- First-half net loss narrowed by $11.3m year over year, principally as R&D expense fell $7.0m and interest income rose $2.6m; collaboration revenue increased $1.1m.
- Management attributed lower R&D expense mainly to timing of manufacturing batches and lower lab-supply and contract-service costs, partly offset by higher clinical-trial expense.
- BDC-1001 completed Phase 1, with a recommended Phase 2 dose established; the company described a Phase 2 program across four HER2-positive solid-tumor types. The FDA cleared BDC-3042’s IND in July 2023, after quarter-end.
- The company terminated a separate Stanford license agreement effective May 10, 2023, determining it was no longer necessary; no payment was due. No shares had been sold under the $75m ATM program as of June 30.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and marketable securities to fund operations for at least 12 months after the filing’s issuance date. Near-term spending priorities include key milestones for BDC-1001 and BDC-3042, clinical trials, manufacturing, R&D and employee costs. The company expects continuing losses and says funding needs may grow as programs advance.
- Additional capital may be needed; equity or debt financing, collaborations or licensing may not be available on favorable terms or at all, and equity issuance could dilute shareholders. The cash-runway estimate is forward-looking and actual spending or results could differ.
- Key risks include clinical and regulatory uncertainty, reliance on single-source manufacturers and suppliers, intellectual-property matters, macroeconomic and geopolitical disruption, and the possibility that collaborations or development plans change. No material legal proceedings or material changes to previously disclosed risk factors were reported.
- Potential future supply-agreement milestone payments are up to $2.0m. The company disclosed no material indemnification claims and no material contingency liability. Collaboration agreements include potential milestone and royalty payments, but these are excluded from transaction prices because their timing and probability cannot currently be estimated.
- Management stated disclosure controls were effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter.
Investor verification priorities
- Confirm subsequent cash use and whether the stated 12-month runway remains supported by updated forecasts and program plans.
- Track BDC-1001 Phase 2 progress, trial costs and results, and BDC-3042 IND-enabling follow-through and clinical development.
- Review collaboration progress, deferred revenue balances and any changes to the Toray research plan or partner funding obligations.
- Assess the timing of manufacturing expenditures, supplier concentration and any potential milestone payments under the supply agreement.
- Monitor future financing activity, including use of the ATM or shelf registration, and resulting dilution.